 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- PORT-6 / Portage
ADPORT-601 (TT-10 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1090;
P1/2
Secondary endpoints include Objective Response Rate, Duration of Response, and Progression-Free Survival. Longitudinal blood and tissue samples will be collected.
- || PORT-7 / Portage
Trial initiation date, Metastases: TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov) - May 2, 2022
P1/2, N=69, Not yet recruiting, Sponsor: Tarus Therapeutics, Inc.
Longitudinal blood and tissue samples will be collected. Initiation date: Sep 2021 --> Dec 2022
- TT-10 / Tarus Therap, TT-4 / Tarus Therap
Adenosine receptor antagonists A2AR (TT-10) and A2BR (TT-4) demonstrate anti-tumor activity in 4T1-induced syngeneic breast cancer mouse model (Section 33) - Mar 9, 2022 - Abstract #AACR2022AACR_5263;
TT-10 & TT-4 alone was superior (p<0.05) to the VC as well as single agent anti-PD-1 in slowing tumor growth, which was further supported by the increase in T-cell activity observed in the end of study TIL analysis. Lastly, striking reductions in MDSC populations were also observed in both TT-10 & TT-4 treated mice, when compared to single agent anti-PD-1 and the VC.
- TT-10 / Tarus Therap, TT-4 / Tarus Therap
Combination of Adenosine antagonists A2AR (TT-10) and A2BR (TT-4) with checkpoint inhibitors demonstrate anti-tumor activity in CT-26 Murine Colon Tumor Allograft Model (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_335;
However, the combination of TT-10 + Anti-mPD-1 and TT-4 + Anti-mCTLA-4 showed the greatest tumor response and growth suppression. Furthermore, a striking reduction of CD25+FoxP3+ within the tumor was observed at day 3 in mice treated with A2AR alone, A2AR + anti-mPD-1 and A2AR + anti-m-CTLA-4 when compared to the vehicle control.
- |||| PORT-7 / Portage
New P1/2 trial, Metastases: TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov) - Jul 26, 2021
P1/2, N=69, Not yet recruiting, Sponsor: Tarus Therapeutics, Inc.